4D Molecular Therapeutics
4D Molecular Therapeutics' revenue rose 230194.6% to $85 million in fiscal 2025. Its operating margin was −187.2%, up from −507,678.4% a year earlier. Free cash flow was −$110 million. The diluted share count rose 7.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What 4D Molecular Therapeutics does
4D Molecular Therapeutics is a late-stage biotechnology company developing gene therapies, which are medicines that deliver genetic instructions into a patient's cells. It builds its own delivery vehicles, called vectors, and has programs in two areas, eye disease and lung disease.
Its lead candidate, 4D-150, uses the company's R100 vector to deliver instructions for making a drug that blocks a growth signal called VEGF. It is in Phase 3 testing for wet age-related macular degeneration, an eye disease that damages central vision, and is preparing for Phase 3 in diabetic macular edema. The goal is a lasting treatment given in the doctor's office that reduces how often patients need treatment. Another candidate, 4D-710, is in Phase 2 for cystic fibrosis.
The company has no products approved for sale and has never earned revenue from product sales. It plans to move 4D-150 through Phase 3 and, if that works, to sell it, while moving its early programs to first human proof of concept.
Its biggest risks, as it describes them
- It has no approved products and a limited operating history, with its lead program in late-stage development.
- It has lost money every year and will need substantial additional capital.
- Its candidates could cause side effects that halt development or block approval.
- Few patients have the diseases it studies, which may make trials harder to finish or to prove.
- Public worry or regulatory scrutiny of genetic medicines could slow its progress.
Income statement
4D Molecular Therapeutics lost money in fiscal 2025: a net loss of $140 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 248 | 214 | 288 | 425 | 514 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 15.7x | 14.0x | 15.7x | 14.9x | 9.4x |
| Quick ratio | 15.7x | 14.0x | 15.7x | 14.9x | 9.4x |
Cash flow
Projections
Project 4D Molecular Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of 4D Molecular Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 183.2% | −374,075.5% | 230,066.0% |
| Altman Z'' | 9.22 | 9.92 | 6.96 |
| Accruals ratio | −8.3% | −5.8% | −5.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put 4D Molecular Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics | FY25 | 230,194.6% | −187.2% | −128.7% | — | — | — | |
| Cytokinetics | FY25 | 376.6% | −695.4% | −607.5% | — | — | — | Compare |
| MeiraGTx | FY25 | 144.6% | −130.2% | −61.7% | — | — | 3 | Compare |
| CytomX Therapeutics | FY25 | −44.8% | −29.4% | −99.5% | — | — | — | Compare |
| Recursion Pharmaceuticals | FY25 | 26.9% | −867.9% | −506.5% | −117.2% | — | 4 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 7 | 14 | 18 | 3 | 21 | 0 | 85 |
| Revenue growth | — | 94.8% | 32.5% | −82.7% | 562.3% | −99.8% | 230,194.6% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 39 | 53 | 61 | 80 | 97 | 141 | 196 |
| Operating income | −51 | −57 | −71 | −110 | −113 | −188 | −160 |
| Net income | −49 | −57 | −71 | −108 | −101 | −161 | −140 |
| Diluted EPS (US$) | −9.59 | −8.82 | −2.57 | −3.32 | −2.58 | −2.98 | −2.42 |
| Diluted shares (millions) | 5 | 6 | 28 | 32 | 39 | 54 | 58 |
| Cash flow | |||||||
| Cash from operations | −37 | −51 | −69 | −87 | −76 | −135 | −109 |
| Capital expenditure | 3 | 1 | 9 | 12 | 3 | 4 | 0 |
| Free cash flow | −40 | −52 | −78 | −98 | −79 | −138 | −110 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 4 | 5 | 14 | 17 | 20 | 26 | 22 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 50 | 277 | 248 | 214 | 288 | 425 | 514 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 58 | 288 | 354 | 262 | 340 | 560 | 567 |
| Total liabilities | 28 | 32 | 34 | 30 | 32 | 50 | 61 |
| Shareholders' equity | −73 | 256 | 319 | 231 | 308 | 511 | 506 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −726.6% | −416.3% | −395.5% | −3,516.5% | −544.6% | −507,678.4% | −187.2% |
| Net margin | −705.8% | −416.5% | −395.4% | −3,435.4% | −486.6% | −434,778.4% | −164.4% |
| Free cash flow margin | −571.3% | −381.4% | −433.8% | −3,139.1% | −379.1% | −373,975.7% | −128.7% |
| Rule of 40 (growth + FCF margin) | — | −286.5% | −401.3% | −3,221.7% | 183.2% | −374,075.5% | 230,066.0% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −61.8% | −24.8% | −39.1% | −37.4% | −39.3% | −27.6% |
| Return on assets | — | −32.7% | −22.2% | −34.9% | −33.5% | −35.7% | −24.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — |